Factors Affecting Suppression of Endogenous Thyrotropin Secretion by Thyroxine Treatment: Retrospective Analysis in Athyreotic and Goitrous Patients*
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Factors affecting TSH suppression by L-T4 administration were retrospectively evaluated in 452 patients: 180 who were athyreotic after total thyroidectomy and remnant radioiodine ablation for differentiated thyroid carcinoma and 272 with nontoxic diffuse or nodular goiter. All patients were considered clinically euthyroid. TSH secretion was assessed by iv TRH stimulation testing. The T4 dose associated with an undetectable basal serum TSH level and no increase in serum TSH after TRH administration (suppressive dose) averaged 2.7 +/- 0.4 (SD) micrograms/kg body weight (BW)/day in athyreotic patients and 2.1 +/- 0.3 micrograms/kg BW/day in goitrous patients (P less than 0.001). The 25th-75th percentile intervals were 2.5-2.9 micrograms/kg BW/day for athyreotic patients and 1.9-2.3 micrograms/kg BW/day for goitrous patients. The suppressive dose of T4 was dependent in both groups on patient age, younger patients needing higher doses than older patients. The duration of treatment also proved to be an important parameter, since in both groups the percentage of patients with suppressed TSH secretion increased if TRH testing was carried out after at least 6 months after the initiation of therapy. Serum total T4, total T3, free T3 (FT3), free T4 (FT4) index, and FT3 index values did not differ in the two groups and were significantly higher (P less than 0.001) than in normal subjects. Mean serum FT4 was significantly higher in athyreotic patients than in goitrous patients with suppressed TSH secretion. Among athyreotic patients with suppressed TSH secretion, 24% had elevated serum FT4 and FT3, and 47% had elevated serum FT4 alone. Of goitrous patients with suppressed TSH secretion, 20% had elevated serum FT4 and FT3, and 27% had elevated serum FT4 alone. On the other hand, 35% of athyreotic patients and 14% of goitrous patients whose TSH secretion was not suppressed had elevated serum FT4. Serum sex hormone-binding globulin concentrations were measured in 3 groups of goitrous women. Values above normal limits were found in 13/26 patients (50%) with high serum FT4 and FT3, in 4/30 patients (13%) with elevated serum FT4 alone, and in 1/25 patients (4%) with normal FT4 and FT3. IN CONCLUSION: TSH suppression requires daily doses of T4 between 2.5 and 2.9 micrograms/kg BW in athyreotic patients and between 1.9 and 2.3 micrograms/kg BW in goitrous patients, with appropriate adjustments in relation to the age of the patient; Assessment of the adequacy of treatment should not be carried out before 6 months after the institution of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Replacement Dosage of L-Thyroxine in Hypothyroidism: A Re-Evaluation
Stock, J. M., Surks, M. I., & Oppenheimer, J. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197403072901001 · Cited by 184
Levothyroxine Replacement Dose for Primary Hypothyroidism Decreases with Age
ROSENBAUM, R. L., & BARZEL, U. S. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-1-53 · Cited by 163
ROSNER, W., ADEN, D. P., & KHAN, M. S. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-4-806 · Cited by 115
Cotton, G. E., Gorman, C. A., & Mayberry, W. E. (1971) · New England Journal of Medicine · doi:10.1056/nejm197109022851001 · Cited by 95
Cited by
Papillary and Follicular Thyroid Carcinoma
Schlumberger, M. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380506 · Cited by 1,623
Cailleux, A. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.175 · Cited by 357
Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective
Schlumberger, M., Berg, G., Cohen, O., Duntas, L., Jamar, F., Jarzab, B., Limbert, E., Lind, P., Pacini, F., Reiners, C., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500105 · Cited by 327
Papillary and follicular thyroid carcinoma
Schlumberger, M. J., & Torlantano, M. (2000) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2000.0105 · Cited by 278
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
Metadata
- Authors
- BARTALENA, L., MARTINO, E., PACCHIAROTTI, A., GRASSO, L., AGHINI-LOMBARDI, F., BURATTI, L., BAMBINI, G., BRECCIA, M., & PINCHERA, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1987-04
- Volume
- 64
- Issue
- 4
- Pages
- 849-855
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1997277674
- Cited by
- 65
- References
- 4
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factors Affecting Suppression of Endogenous Thyrotropin Secretion by Thyroxine Treatment: Retrospective Analysis in Athyreotic and Goitrous Patients*. https://app.cochat.ai/papers/10.1210/jcem-64-4-849
- The paper
- BARTALENA, L., MARTINO, E., PACCHIAROTTI, A., GRASSO, L., AGHINI-LOMBARDI, F., BURATTI, L., BAMBINI, G., BRECCIA, M., & PINCHERA, A. (1987). Factors Affecting Suppression of Endogenous Thyrotropin Secretion by Thyroxine Treatment: Retrospective Analysis in Athyreotic and Goitrous Patients*. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem-64-4-849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.